KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash & Equivalents: 2018-2025

Historic Cash & Equivalents for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Sep 2025 value amounting to $73.2 million.

  • Aurinia Pharmaceuticals' Cash & Equivalents rose 97.05% to $73.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year increase of 97.05%. This contributed to the annual value of $83.4 million for FY2024, which is 70.71% up from last year.
  • Aurinia Pharmaceuticals' Cash & Equivalents amounted to $73.2 million in Q3 2025, which was up 38.09% from $53.0 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Cash & Equivalents registered a high of $231.9 million during Q4 2021, and its lowest value of $33.4 million during Q2 2024.
  • For the 3-year period, Aurinia Pharmaceuticals' Cash & Equivalents averaged around $61.5 million, with its median value being $64.5 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 76.85% in 2021, then soared by 97.05% in 2025.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Cash & Equivalents stood at $231.9 million in 2021, then crashed by 59.39% to $94.2 million in 2022, then crashed by 48.10% to $48.9 million in 2023, then soared by 70.71% to $83.4 million in 2024, then soared by 97.05% to $73.2 million in 2025.
  • Its last three reported values are $73.2 million in Q3 2025, $53.0 million for Q2 2025, and $66.4 million during Q1 2025.